文献速递消化系统肿瘤

白蛋白结合型紫杉醇联合吉西他滨在老年与年轻转移性胰腺癌患者中的比较:多中心前瞻性非干预研究分析

Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study.
PubMed 文献 · Eur J Cancer · 2020-12-06

本研究为多中心前瞻性非干预研究,比较≤70岁与>70岁转移性胰腺癌患者接受白蛋白结合型紫杉醇联合吉西他滨(nab-P/G)的耐受性与疗效。共317例患者入组,299例可分析(≤70岁162例,>70岁137例)。两组安全谱总体相当,但老年组疲乏和食欲下降更常见;客观缓解率、无进展生存期和总生存期在两组间相似。

要点

  • nab-P/G在>70岁转移性胰腺癌患者中可行且耐受,疗效与≤70岁患者相似。
  • 老年组疲乏(22.8% vs 13.0%)和食欲下降(8.8% vs 1.2%)更常见。
  • 两组中位OS分别为10.6个月(≤70岁)和10.2个月(>70岁),HR=0.89,p=0.4。

核心结论

  • 真实世界分析证实nab-P/G在转移性胰腺癌中的可行性和耐受性,>70岁与≤70岁患者的总生存期相似。

研究设计与样本

  • 多中心、前瞻性、非干预性研究,入组317例转移性胰腺癌患者,中位年龄70岁,299例符合分析(≤70岁162例,>70岁137例)。

主要发现

  • 两组基线特征和安全谱总体相当,但老年组疲乏(22.8% vs 13.0%)和食欲下降(8.8% vs 1.2%)更常见。
  • 客观缓解率≤70岁组36% vs >70岁组48%,中位无进展生存期5.6 vs 5.5个月(HR=1.03,p=0.81)。
  • 中位总生存期10.6 vs 10.2个月(HR=0.89,p=0.4),中位治疗周期数5 vs 4,相对剂量强度70% vs 74%。
  • 多数患者(56.2% vs 47.4%)接受了二线治疗。

临床怎么用

  • 对于>70岁转移性胰腺癌患者,nab-P/G可作为可行的治疗选择,但需关注疲乏和食欲下降等不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pancreatic cancer (PC) ranks among the deadliest malignancies worldwide. In the MPACT study, first-line nab-paclitaxel plus gemcitabine (nab-P/G) demonstrated activity (median overall survival [OS], 8.7 months) and tolerability in patients with metastatic PC (mPC). However, the clinical evidence of nab-P/G in the elderly (>70 years), who account for the majority of patients with mPC, is limited. This is the first prospective, multicentre, non-interventional study evaluating the tolerability and effectiveness of nab-P/G in younger (≤70 years) versus elderly (>70 years) patients with mPC in the daily clinical routine. METHODS: Eligible patients with mPC were treated with nab-P/G and observed until disease progression or unacceptable toxicity. The primary objectives were safety and tolerability of nab-P/G, and the secondary objectives were efficacy and real-life dosing. RESULTS: A total of 317 patients with mPC (median age, 70 years) were recruited, of which 299, aged ≤70 (n = 162) and >70 (n = 137) years, were eligible for analysis. Baseline characteristics and the safety profile were comparable between the groups. However, fatigue (22.8% versus 13.0%) and decreased appetite (8.8% versus 1.2%) were more frequent in elderly patients. Younger versus elderly patients equally benefited in terms of objective response rate (36% versus 48%), median progression-free survival (5.6 versus 5.5 months; hazard ratio [HR] = 1.03; p = 0.81) and OS (10.6 versus 10.2 months; HR = 0.89; p = 0.4). In addition, the median treatment duration (5 versus 4 cycles), relative dose intensity (70% versus 74%) or reasons for treatment discontinuation were similar. Most patients (56.2% versus 47.4%) benefited from a second-line therapy. CONCLUSION: This prospective real-world analysis confirms the feasibility and tolerability of nab-P/G treatment and reveals OS data similar for younger patients and elderly patients aged >70 years. CLINICALTRIALS. GOV REGISTRATION: NCT02555813. AUSTRIAN NIS REGISTRY: NIS005071.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Prager GW, Oehler L, Gerger A, et al. Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study. Eur J Cancer. 2020. PMID: 33296830. doi:10.1016/j.ejca.2020.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。